SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) November 13, 2000
BICO, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822
(State of other jurisdiction of Incorporation) (Commission File Number)
25-1229323
(IRS Employer Identification No.)
2275 Swallow Hill Road, Bldg. 2500
Pittsburgh, Pennsylvania 15220
(Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code (412) 429-0673
___________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On November 14, 2000, BICO announced its
acceptance of David L. Purdy's resignation as
president of its Biocontrol Technology, Inc.
subsidiary. The Company has commenced a search for
his replacement. BICO also confirmed that it has,
and will continue to, fund and support the
Diasensor project (press release attached).
BICO acknowledges that a press release was
evidently issued by persons at its Biocontrol
Technology, Inc. division on November 13, 2000;
that press release was not authorized by BICO, and
it was not reviewed in compliance with BICO's
corporate policy regarding the dissemination of
non-public information. As a result, the
Biocontrol Technology press release dated November
13, 2000 will not be filed as an exhibit to Form 8-
K. BICO believes that the press release dated
November 14, 2000, and attached hereto as an
exhibit, properly addresses the issues raised in
the November 13, 2000 press release.
Item 6. Resignation of Registrant's Directors.
Not Applicable.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Business Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
Press Release dated November 14, 2000
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
BICO, INC.
By: /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: November 14, 2000
BICO ACCEPTS RESIGNATION OF DIVISION HEAD
Pittsburgh, PA - November 14, 2000 - BICO, Incorporated
(OTCBB:BIKO) announced today that it has accepted the
resignation of David L. Purdy, 72, President of the
Biocontrol Technology, Inc. division.
Fred E. Cooper, CEO of BICO, said, "We regret the
resignation of Mr. Purdy, who has made significant
contributions in the development of the noninvasive glucose
sensor technology. However, BICO assures the shareholders
that it will move swiftly to replace Mr. Purdy and that the
Diasensor 2000 project will continue to be funded and
supported by BICO, as it has since 1989."
To date in year 2000, BICO has funded the Diasensor
project in excess of $14 million, which exceeds budget
requirements by over $1 million.
Currently, the Diasensor is in clinical trials designed
and conducted by the Joslin Diabetes Center in Boston.
To announce his resignation, Mr. Purdy issued a press
release wherein he also took issue with information recently
released to BICO subsidiary Diasensor.com shareholders. Of
those comments, Mr. Cooper said, "I feel it is important to
say that the Company agrees with Mr. Purdy's comments that
many issues need to be addressed before the stock of
Diasensor.com is liquid, that FDA approval depends upon the
successful outcome data of the Joslin trials, and that the
Diasensor 2000 is not intended for use by all diabetics.
BICO has never maintained otherwise. At this time, however,
the Company cannot confirm Mr. Purdy's definition of the
market size for the Diasensor."
BICO, Inc. has its corporate offices in Pittsburgh, PA
and is involved in the development and manufacture of
biomedical devices and environmental products. Biocontrol
Technology, Inc., a division of BICO located in Indiana, PA,
focuses on the research, development, and manufacturing of
the Diasensor noninvasive glucose sensor and other
biomedical products.
FOR FURTHER INFORMATION, CONTACT:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
WEBSITE: www.bico.com